The first participants in an early stage clinical trial have received a dose of the mRNA flu shot, and Moderna plans to enroll about 180 people.
Moderna said mRNA technology could provide advantages over current flu shot technology, which is only about 40 percent to 60 percent effective and takes six to nine months to prepare.
An mRNA flu shot could also be combined with other vaccines, including a COVID-19 vaccine, so one shot could provide protection from multiple viruses.
“Our vision is to develop an mRNA combination vaccine so that people can get one shot each fall for high efficacy protection against the most problematic respiratory viruses,” Moderna CEO Stéphane Bancel said in a news release.
Read the full news release here.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
